Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
760 USD | -1.50% | +3.41% | +30.38% |
May. 10 | Cipla Open to Partner With Eli Lilly to Market Obesity Drugs in India | MT |
May. 10 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
Financials (USD)
Sales 2024 * | 42.81B | Sales 2025 * | 52.47B | Capitalization | 684B |
---|---|---|---|---|---|
Net income 2024 * | 11.93B | Net income 2025 * | 16.55B | EV / Sales 2024 * | 16.5 x |
Net Debt 2024 * | 19.98B | Net Debt 2025 * | 15.29B | EV / Sales 2025 * | 13.3 x |
P/E ratio 2024 * |
56.8
x | P/E ratio 2025 * |
40.9
x | Employees | 43,000 |
Yield 2024 * |
0.68% | Yield 2025 * |
0.79% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 day | -1.50% | ||
1 week | +3.41% | ||
Current month | -2.70% | ||
1 month | +1.11% | ||
3 months | +3.08% | ||
6 months | +27.15% | ||
Current year | +30.38% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.49% | 0 M€ | +7.69% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 760 | -1.50% | 2,082,289 |
24-05-09 | 771.6 | -0.45% | 2,522,085 |
24-05-08 | 775 | -0.36% | 2,089,934 |
24-05-07 | 777.8 | +1.45% | 2,879,447 |
24-05-06 | 766.7 | +4.31% | 3,398,280 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- LLY Stock